TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients

Only a minority of myelodysplastic syndrome (MDS) patients respond to hypomethylating agents (HMAs), but strong predictors of response are unknown. We sequenced 40 recurrently mutated myeloid malignancy genes in tumor DNA from 213 MDS patients collected before treatment with azacitidine (AZA) or dec...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Bejar, Rafael, Lord, Allegra, Stevenson, Kristen, Bar-Natan, Michal, Pérez-Ladaga, Albert, Zaneveld, Jacques, Wang, Hui, Caughey, Bennett, Stojanov, Petar, Getz, Gad, Garcia-Manero, Guillermo, Kantarjian, Hagop, Chen, Rui, Stone, Richard M., Neuberg, Donna, Steensma, David P., Ebert, Benjamin L.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2014
Assuntos:
Myeloid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4208285/
https://ncbi.nlm.nih.gov/pubmed/25224413
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-06-582809
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados